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Abstract
Recombinant human erythropoietin (rHuEpo) increases haemoglobin mass (Hbmass) and maximal oxygen uptake (v˙ O2 max).
Purpose: This study defined the time course of changes in Hbmass, v˙ O2 max as well as running time trial performance
following 4 weeks of rHuEpo administration to determine whether the laboratory observations would translate into actual
improvements in running performance in the field.
Methods: 19 trained men received rHuEpo injections of 50 IUNkg21 body mass every two days for 4 weeks. Hbmass was
determined weekly using the optimized carbon monoxide rebreathing method until 4 weeks after administration. v˙ O2 max
and 3,000 m time trial performance were measured pre, post administration and at the end of the study.
Results: Relative to baseline, running performance significantly improved by ,6% after administration (10:3061:07 min:sec
vs. 11:0861:15 min:sec, p,0.001) and remained significantly enhanced by ,3% 4 weeks after administration
(10:4661:13 min:sec, p,0.001), while v˙ O2 max was also significantly increased post administration
(60.765.8 mLNmin21Nkg21 vs. 56.066.2 mLNmin21Nkg21, p,0.001) and remained significantly increased 4 weeks after
rHuEpo (58.065.6 mLNmin21Nkg21, p = 0.021). Hbmass was significantly increased at the end of administration compared to
baseline (15.261.5 gNkg21 vs. 12.761.2 gNkg21, p,0.001). The rate of decrease in Hbmass toward baseline values post
rHuEpo was similar to that of the increase during administration (20.53 gNkg21Nwk21, 95% confidence interval (CI) (20.68,
20.38) vs. 0.54 gNkg21Nwk21, CI (0.46, 0.63)) but Hbmass was still significantly elevated 4 weeks after administration
compared to baseline (13.761.1 gNkg21, p,0.001).
Conclusion: Running performance was improved following 4 weeks of rHuEpo and remained elevated 4 weeks after
administration compared to baseline. These field performance effects coincided with rHuEpo-induced elevated v˙ O2 max and
Hbmass.
Citation: Durussel J, Daskalaki E, Anderson M, Chatterji T, Wondimu DH, et al. (2013) Haemoglobin Mass and Running Time Trial Performance after Recombinant
Human Erythropoietin Administration in Trained Men. PLoS ONE 8(2): e56151. doi:10.1371/journal.pone.0056151
Editor: Elias T. Zambidis, Johns Hopkins School of Medicine, United States of America
Received October 23, 2012; Accepted January 5, 2013; Published February 13, 2013
Copyright:  2013 Durussel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was part of a larger research project supported and funded by World Anti-Doping Agency (08C19YP). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Yannis.Pitsiladis@glasgow.ac.uk
Introduction
Erythropoietin is a glycoprotein hormone produced primarily in
the kidney that regulates red blood cell mass by stimulating the
survival, proliferation and differentiation of erythrocytic progen-
itors [1]. In healthy subjects, administration of recombinant
human erythropoietin (rHuEpo) increases haemoglobin concen-
tration not only by the well known increase in red blood cell mass
but also by a decrease in plasma volume [2,3,4]. The decrease in
plasma volume, which precedes the increase in red cell mass,
appears to be a rapid responding mechanism regulated by the
renin-angiotensin-aldosterone system to control haematocrit [2,3].
Theoretically, normal human red blood cells can persist in the
circulation for approximately 17 weeks [5]. However, neocytolysis,
the selective hemolysis of young circulating red blood cells which
contributes to the regulation of red cell mass, seems to appear
during specific conditions that cause a rapid decrease in
erythropoietin levels such as spaceflight, high altitude exposure
or blood doping [5,6,7,8,9]. Little is known about the time course
of these mechanisms post rHuEpo administrations. In this study,
heamoglobin mass (Hbmass) and related blood volumes were
repeatedly determined using the optimized carbon monoxide (CO)
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rebreathing method [10,11] pre, during and post rHuEpo
administration in healthy trained men.
Most studies investigating the effects of rHuEpo on exercise
performance have used maximal oxygen uptake (v˙ O2 max) tests.
However, v˙ O2 max tests alone may be of little help in predicting
exercise performance among athletes of similar ability
[12,13,14,15]. One study assessed submaximal performance in
healthy male subjects and reported improvements of more than
50% in time to exhaustion on a cycle ergometer at a given 80% of
v˙ O2 max whereas the increase in v˙ O2 max was approximately 12%
[16]. Despite being a very interesting finding which questions the
mechanisms by which rHuEpo improves submaximal exercise
performance [17], the validity of the time to exhaustion test in
assessing human exercise performance has been questioned [18].
In addition to being more variable than time trial tests [19], time
to exhaustion tests are less likely to mimic the exercise
performance environment [18,19]. There are indeed only minimal
occasions where an athlete is required to maintain a constant
intensity until volitional exhaustion compared with self-paced
exercise [18,19].
The main purpose of the present study was to investigate the
time course of Hbmass and related blood parameters as well as
changes in running 3,000 m time trial performance following 4
weeks of rHuEpo administration in healthy trained men in order
to determine whether the augmented v˙ O2 max observed in
laboratory based experiments would translate into actual im-
provements in running performance in the field.
Methods
Ethics Statement
This study was approved by University of Glasgow Ethics
Committee and conformed to the Declaration of Helsinki. All
subjects underwent a medical assessment and provided written
informed consent to participate. This study was part of a larger
research project funded by the World Anti-Doping Agency
(WADA).
Subjects
Nineteen healthy non-smoking trained men (mean 6 SD, age:
26.064.5 yr, body mass: 74.867.9 kg, height: 179.865.4 cm)
participated in this study. The subjects were regularly engaged in
predominantly endurance-based activities such as running,
cycling, swimming, triathlon and team sports. The subjects were
divided into two groups for exercise performance analysis. The
first group included subjects who had a history of running (n= 10)
and the second group included the remaining subjects who were
involved in other sporting activities (n = 9). Subjects were
requested to maintain their normal training but abstain from
official sporting competition for the duration of the research
protocol. One of the subjects in the running group suffered from
nasal obstruction and coughing during the study and could not
perform the time trials post rHuEpo administration. The running
performance data of this subject was excluded from the analyses.
Experimental Design
Each subject subcutaneously self-injected 50 IUNkg21 body
mass of rHuEpo (NeoRecormon, Roche, Welwyn Garden City,
UK) every second day for 4 weeks. Daily oral iron supplemen-
tation (, 100 mg of elemental iron, Ferrous Sulphate Tablets,
Almus, Barnstaple, UK) was given during the 4 weeks of
rHuEpo administration. Venous blood samples from an
antecubital vein were obtained in triplicate at baseline (over 2
weeks prior to the first rHuEpo administration), during rHuEpo
administration (on days 2, 4, 8, 10, 14, 16, 20, 22, 26, 28) and
for 4 weeks after rHuEpo administration (on days 30, 35, 41,
43, 48, 50, 57). All blood samples were taken after 10 min of
rest in the supine position [20]. Blood samples were homoge-
nized using a roller mixer and then measured in triplicate using
a Sysmex XT-2000i (Sysmex UK, Milton Keynes, UK). The
mean value of the triplicate was reported. Resting blood
pressure and heart rate were recorded three times on both arms
in the supine position before blood sampling using an
automated cuff oscillometric device (Boso-Medicus, Bosch &
Sohn GmbH, Jungingen, Germany).
Measurements of Haemoglobin Mass and Related Blood
Volumes
Hbmass was determined in triplicate prior to the first rHuEpo
injection and then weekly up to 4 weeks post rHuEpo
administration using the optimized CO-rebreathing method as
previously described [10,11]. Briefly, a bolus of chemically pure
CO dose of 1.0 mLNkg21 body mass was administered with the
first breath through a spirometer and rebreathed for 2 min with
4 L of oxygen. Change in percent carboxyhaemoglobin in venous
blood samples from baseline to 8 min after CO administration was
measured using a blood gas analyzer (ABL 725, Radiometer,
Copenhagen, Denmark). CO concentration was measured using
the Pac 7000 Draeger CO-analyzer (Draeger Safety, North-
umberland, UK) and an estimated alveolar ventilation of
7.5 lNmin21 was used for calculations. Hbmass as well as blood,
red cell and plasma volume were calculated as previously
described elsewhere [11]. Blood volume was derived by dividing
Hbmass by the haemoglobin concentration. Red cell volume was
obtained by multiplying blood volume by the haematocrit and
plasma volume was then calculated by subtracting red cell volume
from blood volume. The typical error of measurement for Hbmass
calculated from the two first baseline measurements was 1.5%
(95% confidence interval (CI) 1.1 to 2.2%). The typical error of
measurement for blood, red cell and plasma volume between the
two weeks prior to the first rHuEpo administration were 2.4%,
1.6% and 3.6% (CI 1.8 to 3.5, 1.2 to 2.4 and 2.7 to 5.3),
respectively.
Running Performance Assessment
Two 3,000 m time trials separated by at least one day rest were
performed on a 200 m indoor athletic track (Kelvin Hall,
Glasgow, UK) pre, post rHuEpo administration and at the end
of the study. Verbal encouragement was given with feedback
provided for the split time and remaining laps. The best
performance on each occasion was used for analysis. The typical
error of measurement for time trial performance calculated from
the two tests on each phase was 1.3% (CI 1.1 to 1.7). Borg’s rating
of perceived exertion (RPE) was recorded at the completion of the
time trial. Temperature and humidity were recorded using a
hygrometer. In addition to the time trial, v˙ O2 max was determined
pre, post rHuEpo administration and at the end of the study using
an incremental test to exhaustion on a motorised treadmill. Both
continuous or discontinuous protocols were used because of other
purposes of the study (the speed was increased by 1 kmNh21Nmin21
or by 2 kmNh21 every 3 min with 3 min of active recovery at a
walking pace between each bout, respectively). Following a 30 min
recovery, v˙ O2 max was verified using a square-wave protocol to
exhaustion at a speed equivalent to the end speed attained during
the incremental test minus 1 kmNh21 [21,22]. Gas exchange was
measured breath by breath using an automated metabolic gas
analysis system (Cosmed Quark b2, Cosmed, Rome, Italy).
Hbmass and Running Performance after rHuEpo
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Statistical Analysis
Individual mean value was calculated when more than one
blood sample was collected per week before further analysis.
Changes over time in Hbmass, blood, red cell and plasma volume
were assessed using t-test to determine whether the slope of these
parameters was significantly different from zero. Time trial
performance, v˙ O2 max and blood parameters data for the key
stages of the study were analyzed using repeated measures
ANOVA. Relationships between time trial performance, v˙
O2 max and Hbmass were assessed using Pearson’s product moment
correlation coefficients.
Results
Running Performance (Table 1)
Running performance data of both groups combined (n= 18)
are presented in this paragraph (Table 1 for separate groups).
Irrespective of running history, time trial performance significantly
improved by ,6% post administration (10:3061:07 min:sec vs.
11:0861:15 min:sec, p,0.001) and remained significantly en-
hanced by ,3% 4 weeks after rHuEpo compared to baseline
(10:4661:13 min:sec vs. 11:0861:15 min:sec, p,0.001). RPE did
not significantly differ between the time trials (p.0.05). Temper-
ature (19.462.8uC) and humidity (46.669.0%) remained relative-
ly constant (p.0.05). Relative to baseline, v˙ O2 max significantly
increased post administration (60.765.8 mLNmin21Nkg21 vs.
56.066.2 mLNmin21Nkg21, p,0.001) and remained significantly
increased 4 weeks after rHuEpo (58.065.6 mLNmin21Nkg21 vs.
56.066.2 mLNmin21Nkg21, p = 0.021). v˙ O2 max was at least
moderately correlated with Hbmass as well as time trial
performance throughout the study (range, r = 0.48 to r = 0.88,
p,0.05). However, a significant correlation in individual responses
compared to baseline between parameter was only observed for
Hbmass and time trial performance at the end of the study
(r =20.68, p= 0.002).
Haematological Parameters and Resting Blood Pressure
and Heart Rate (Tables 2 and 3)
Table 2 illustrates the changes in the main haematological
parameters for five key stages of the study. Relative to baseline
values, both haematocrit and haemoglobin concentration gradu-
ally increased throughout the rHuEpo administration to reach a
maximum approximately one week after the last injection
(p,0.001) and remained significantly elevated 4 weeks post
rHuEpo administration (p,0.001). Reticulocyte percent increased
rapidly after the first two weeks of injections (p,0.001). Nadir with
a very low inter-subject variation was reached approximately two
weeks after injections ceased, which was significantly lower
compared with baseline values (p,0.001). Body mass did not
change during the study. rHuEpo administration did not induce
any significant changes in resting systolic and diastolic blood
pressure as well as in resting heart rate.
Haemoglobin Mass and Blood Volumes (Tables 2, 4 and
Fig. 1)
Relative to baseline, Hbmass and plasma volume were signifi-
cantly increased (p,0.001) and decreased (p = 0.004) at the end of
the rHuEpo administration, respectively. Hbmass and red cell
volume gradually increased by approximately 40 gNwk21
(p,0.001) and 135 mLNwk21 (p,0.001), respectively (Fig. 1A
and 1B). Plasma volume decreased significantly by approximately
100 mLNwk21 (p,0.001) (Fig. 1C) while blood volume remained
relatively unchanged (p= 0.32) (Fig. 1D). From week 1 to week 4
post rHuEpo administration, the rate of decrease in Hbmass and
red cell volume toward baseline values was similar to that of the
increase during administration (Fig. 1A and 1B) but both Hbmass
and red cell volume were still significantly elevated 4 weeks post
administration compared to baseline (p,0.001). Plasma volume
was restored to pre-injection levels 4 weeks post administration
(p = 0.108) (Fig. 1C).
Carboxyhaemoglobin (Table 2 and Fig. 2)
Relative to baseline values, basal percentage of carboxyhaemo-
globin prior to the CO-rebreathing procedure was significantly
elevated at the end of the rHuEpo administration (p,0.001).
Percentage of carboxyhaemoglobin returned to pre-injection
values 4 weeks post rHuEpo administration.
Discussion
The aim of this study was to investigate the time course of
Hbmass and related blood parameters as well as changes in running
3,000 m time trial performance following 4 weeks of rHuEpo
administration in order to determine whether the augmented v˙
O2 max would translate into actual improvements in running
performance in the field. The main findings of this study are that,
relative to baseline, running performance was significantly
improved following 4 weeks of rHuEpo administration and
remained significantly elevated 4 weeks post administration and
Table 1. Running 3,000 m time trial performance and maximal oxygen uptake.
Group 1 Group 2
Baseline
End of
rHuEpo
End of the
study Baseline
End of
rHuEpo
End of the
study
3,000 m total time (min:sec) 10:12 (0:42) 9:40* (0:37) 9:53* (0:43) 12:05 (0:55) 11:19* (0:53) 11:39* (0:58)
1st 1,000 m split (min:sec) 3:16 (0:13) 3:10* (0:12) 3:13 (0:13) 3:53 (0:27) 3:36* (0:14) 3:41 (0:20)
2nd 1,000 m split (min:sec) 3:26{ (0:16) 3:15*{ (0:14) 3:20{ (0:14) 4:05 (0:17) 3:54{ (0:26) 3:59{ (0:20)
3rd 1,000 m split (min:sec) 3:29{ (0:15) 3:15* (0:13) 3:20* (0:16) 4:07 (0:16) 3:49*{ (0:15) 3:59{ (0:19)
RPE scale (6–20) 18.0 (1.7) 18.4 (0.9) 19.0 (1.2) 17.7 (2.2) 18.4 (1.6) 18.6 (1.4)
O2 max (mLNmin
21
Nkg21) 60.3 (5.0) 64.4* (3.9) 61.8 (3.4) 51.6 (3.5) 57.0* (5.1) 54.2* (4.7)
Group 1 included subjects who had a history of running (n = 9) and group 2 included the other subjects who were involved in other activities (n = 9). Values are means
(SD). Significant differences compared to baseline values are indicated by *P,0.05. Significant differences compared to the first 1,000 m split time within the same time
trial. {P,0.05. RPE: Borg’s rating of perceived exertion; O2 max: Maximal oxygen uptake.
doi:10.1371/journal.pone.0056151.t001
Hbmass and Running Performance after rHuEpo
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that these performance effects coincided with significantly
rHuEpo-induced elevated v˙ O2 max and Hbmass.
Running Performance
The effects of rHuEpo on exercise performance have principally
been investigated using v˙ O2 max tests. Despite slight differences in
the frequency of injections and in the dosage used, rHuEpo
administration for 4 to 6 weeks in healthy subjects has been shown
to increase v˙ O2 max by approximately 8%, which was confirmed
by our observations [23,24,25,26,27,28,29]. However, v˙ O2 max
considerably varies among professional athletes [30,31] and v˙
O2 max tests alone may be of little help in determining and ranking
exercise performance when athletes of similar endurance ability
are compared [12,13,14,15]. Time trial performance more closely
reproduces competition conditions and more importantly allows
the subjects to choose their own pace. It has previously been
observed that blood doping via one unit of autologous blood
transfusion, which increased the haematocrit by 5%, improved
10,000 m running performance by approximately one minute in 6
highly trained male distance runners, which corresponded to a
,3% improvement [32]. However, to our knowledge, no study
has measured running time trial performance in order to
determine whether the augmented v˙ O2 max after rHuEpo
administration would translate into actual improvements in
performance in the field.
Relative to baseline, running performance improved post
rHuEpo administration and remained enhanced 4 weeks after
administration by approximately 6% and 3%, respectively.
Following rHuEpo administration, subjects were able to maintain
a faster pace throughout the 3,000 m time trial compared to
baseline. While the augmented oxygen transport capacity
illustrated by the increase in Hbmass can explain the increase in
v˙ O2 max post rHuEpo administration, it cannot really explain the
significant improvement in running performance. Indeed, as
oxygen supply and demand are adequately matched during
submaximal exercise in healthy men, the rHuEpo-induced
augmented oxygen transport capacity cannot be the reason of
the improvement in time trial running performance observed in
our study [12,17]. In addition, failure to observe a strong
correlation between individual changes in v˙ O2 max, Hbmass and
running performance may imply that rHuEpo administration
improves submaximal exercise performance by other mechanisms,
although it could also be partly explained by the limited sensitivity
of the methods of measurement and by the limitations of the study
(see next paragraph). Other mechanisms than the increase in
oxygen transport capacity have been proposed to explain the
effects of rHuEpo on exercise performance [33,34]. For instance, it
has been demonstrated that self-reported mood, cognitive function
and perceived physical condition were improved following
rHuEpo administration [35,36]. rHuEpo may indeed exert effects
in nonhematopoietic tissues including the brain [37,38,39].
Admittedly, two different studies conducted by the same research
group did not reveal any measurable nonhematopoietic ergogenic
effect of rHuEpo on exercise performance and the authors
therefore concluded that the increased oxygen carrying capacity is
the main if not the only reason why rHuEpo enhances exercise
performance in healthy men [40,41]. On the other hand, the
central governor model can give an alternative view [12]. As the
perception of effort of the subjects did not change and because the
subjects were not limited by an inadequate oxygen supply neither
before nor after administration as they ran at submaximal levels,
the central governor model would argue that the subjects ran
faster after rHuEpo administration because of greater recruitment
of motor units allowed by a control mechanism of feed-forward
and feedback to the brain [12; especially Fig. 2 of that paper].
This study was part of a larger research project funded by
WADA and was designed primarily for other purposes. The
present study was not blinded, did not include a control group and
the subjects, yet involved in endurance activities, were not all
runners. As such, we were unable to adequately assess changes in
the training load during the study due to the absence of a placebo
group and the heterogeneity of sporting/training activity of the
subjects. It cannot totally be excluded that the performance
enhancements observed may, therefore, be partly due to placebo
effect, to an increase in the training load and to an improvement in
pacing strategy especially for the non-runners. It was however
reassuring that the typical error of measurement for the two time
trials conducted on each phase was low and that the amplitude of
the improvement observed was well above the confidence interval.
Haemoglobin Mass and Haematological Parameters
The level of Hbmass prior to the intervention reflected the
regular participation in endurance activities of the subjects [42].
Following the first week of rHuEpo administration, Hbmass
Table 2. Haematocrit, haemoglobin concentration, reticulocytes, haemoglobin mass, blood volumes, carboxyhaemoglobin and
body mass before, during and 4 weeks post rHuEpo administration.
Baseline Week 2 of rHuEpo End of rHuEpo
Week 2 post
rHuEpo
Week 4 post
rHuEpo
Haematocrit (%) 41.9 (1.8) 44.7 (2.0)* 49.2 (2.0)* 47.7 (2.2)* 45.1 (1.7)*
Haemoglobin (gNdl21) 14.4 (0.7) 15.2 (0.7)* 16.7 (0.9)* 16.1 (0.9)* 15.6 (0.7)*
Reticulocytes (%) 1.07 (0.31) 2.57 (0.44)* 1.46 (0.41)* 0.44 (0.13)* 0.55 (0.15)*
Hbmass (gNkg
21) 12.7 (1.2) 13.4 (1.3)* 15.2 (1.5)* 15.1 (1.4)* 13.7 (1.1)*
Hbmass (g) 947 (109) 1001 (127)* 1131 (131)* 1126 (136)* 1023 (132)*
Blood volume (L) 6.6 (0.9) 6.6 (1.0) 6.8 (0.8) 6.7 (0.9) 6.6 (0.8)
Red cell volume (L) 2.8 (0.3) 2.9 (0.3)* 3.3 (0.4)* 3.3 (0.4)* 3.0 (0.4)*
Plasma volume (L) 3.8 (0.6) 3.7 (0.7) 3.5 (0.4)* 3.4 (0.6)* 3.6 (0.5)
Carboxyhaemoglobin (%) 0.73 (0.15) 0.77 (0.16) 1.04 (0.19)* 1.01 (0.20)* 0.65 (0.15)
Body mass (kg) 75.1 (8.4) 74.7 (7.8) 75.0 (7.9) 74.6 (7.6) 74.6 (7.5)
N=19. Values are means (SD). Significant differences compared to baseline values are indicated by *P,0.05. Hbmass: Haemoglobin mass.
doi:10.1371/journal.pone.0056151.t002
Hbmass and Running Performance after rHuEpo
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gradually increased and reached its maximum one week after the
last injection. The weekly increase of approximately 40 g is
equivalent to the haemoglobin contained in one bag of 450 mL
stored blood [43]. The delay of approximately one week between
rHuEpo injections and the observed responses in Hbmass and red
cell volume is explained by the reticulocyte maturation time of 1–4
Figure 1. Individual changes in Hbmass (A), red cell (B), plasma (C) and blood (D) volume. Each line corresponds to one subject and each
symbol corresponds to the same subject in all figures. Individual mean value was calculated when more than one blood sample was collected per
week. The bar graphs represent the mean values of the 19 subjects. The grey bars represent the 4 weeks of rHuEpo administration.
doi:10.1371/journal.pone.0056151.g001
Table 3. Resting blood pressure and heart rate before, during and 4 weeks post rHuEpo administration.
Baseline
Week 2 of
rHuEpo
End of
rHuEpo
Week 2 post
rHuEpo
Week 4 post
rHuEpo
Systolic blood pressure (mmHg) 128 (9) 126 (7) 126 (6) 126 (7) 124 (7)
Diastolic blood pressure (mmHg) 70 (8) 69 (8) 69 (7) 70 (7) 69 (8)
Heart rate (beatsNmin21) 62 (8) 60 (7) 60 (7) 59 (7) 61 (8)
N=19. Values are means (SD). No significant differences compared to baseline values were observed.
doi:10.1371/journal.pone.0056151.t003
Hbmass and Running Performance after rHuEpo
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days [44]. While normal human red blood cells can theoretically
persist in the circulation for approximately 17 weeks [5], Hbmass
and red cell volume started to decrease toward baseline values
from approximately the second week post rHuEpo administration
with a similar rate to that of the increase during administration.
This decrease in Hbmass and red cell volume post rHuEpo
administration entailed the haemolysis of circulating red blood
cells and therefore the release of heme from heamoglobin [45].
The heme degradation is catalyzed by heme oxygenase and
generates one molecule of CO per molecule of heme oxidized
[46]. The CO produced by heme metabolism represents more
than 85% of the endogenous CO production in healthy non-
smoking subjects [46]. Although measurement of blood carboxy-
haemoglobin is influenced by environmental factors such as air
pollution [5], carboxyhaemoglobin can be used as an index of
haemolysis [47]. Indeed, basal carboxyhaemoglobin levels in-
creased at the end of the rHuEpo administration and remained
elevated for 2 weeks post administration reflecting accelerated
haemolysis. Despite being only an indirect marker, these results
are in agreement with the negative regulation of red cell mass by
neocytolysis when supraphysiologic red cell mass and endogenous
erythropoietin suppression occur (induced by rHuEpo adminis-
tration, for instance) [7,8]. In addition, this study confirmed that 4
weeks of rHuEpo administration sufficient to induce a significant
increase in haematocrit did not increase resting blood pressure in
healthy subjects when blood pressure was assessed by standard
techniques compared to intra-arterial pressure transducers [40].
This study also demonstrates that the optimized CO-rebreathing
method performed weekly for ten weeks is safe and well tolerated
by healthy subjects.
Plasma Volume
Apart from confirming previous observations that rHuEpo
administration increases haemoglobin concentration by increasing
Table 4. Changes in haemoglobin mass, blood, red cell and plasma volume during and for 4 weeks post rHuEpo administration.
rHuEpo Post rHuEpo
Haemoglobin mass (gNkg21Nwk21) 0.54 (0.46 to 0.63)* 20.53 (20.68 to 20.38)*
Blood volume (mLNkg21Nwk21) 0.34 (20.36 to 1.05) 20.60 (21.20 to 0.00)
Red cell volume (mLNkg21Nwk21) 1.80 (1.50 to 2.10)* 21.77 (22.22 to 21.33)*
Plasma volume (mLNkg21Nwk21) 21.30 (21.94 to 20.66)* 0.50 (0.10 to 0.90)*
N=19. Values are means (95% confidence interval). Significant changes are indicated by *P,0.05.
doi:10.1371/journal.pone.0056151.t004
Figure 2. Individual changes in carboxyhaemoglobin. Each line corresponds to one subject. Individual mean value was calculated when more
than one blood sample was collected per week. The bar graphs represent the mean values of the 19 subjects. The grey bars represent the 4 weeks of
rHuEpo administration.
doi:10.1371/journal.pone.0056151.g002
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Hbmass and by decreasing plasma volume [2,3], the present study
showed that plasma volume returned to pre-injection values only
approximately 4 weeks post rHuEpo administration. Previous
studies have concluded that plasma volume returned rather
rapidly toward baseline value thus restoring pre-administration
haemoglobin concentration values without affecting red cell
volume [3,4]. Olsen et al. [3] used injections of 5000 IU rHuEpo
administered every second day for 2 weeks and thereafter only
once a week for the 2 consecutive weeks to demonstrate that
rHuEpo down-regulates the renin-angiotensin-aldosterone system
as well as the rate of proximal renal tubular reabsorption and
glomerular filtration. The longer and more contrasted rHuEpo
administration regimen used in the present study with a more
abrupt erythropoiesis stimulation termination may have induced a
more profound down-regulation of the renin-angiotensin-aldoste-
rone system and therefore, may explain why plasma volume had
not been restored until 4 weeks after rHuEpo administration. In
agreement with previous findings which used a similar rHuEpo
regimen than the present study, pre-injection haemoglobin
concentration values were not restored 4 weeks post administra-
tion [28].
In conclusion, relative to baseline, running performance was
significantly improved following 4 weeks of rHuEpo administra-
tion in trained men and remained significantly elevated 4 weeks
after administration by approximately 6% and 3%, respectively.
These performance effects coincided with significantly rHuEpo-
induced elevated v˙ O2 max and Hbmass.
Acknowledgments
The authors wish to specially thank the subjects for their participation and
cooperation. We would like also to thank students who helped with data
collection as well as the members of the WADA Project (08C19YP)
Steering Committee and especially Professor T.D. Noakes, Dr. S.
Padmanabhan and Dr. G. Gmeiner.
Author Contributions
Conceived and designed the experiments: JD YPP. Performed the
experiments: JD ED MA TC DHW NP RKP. Analyzed the data: JD
MA JDM YPP. Contributed reagents/materials/analysis tools: YPP.
Wrote the paper: JD YPP.
References
1. Jelkmann W (2011) Regulation of erythropoietin production. J Physiol 589:
1251–1258.
2. Lundby C, Thomsen JJ, Boushel R, Koskolou M, Warberg J, et al. (2007)
Erythropoietin treatment elevates haemoglobin concentration by increasing red
cell volume and depressing plasma volume. J Physiol 578: 309–314.
3. Olsen NV, Aachmann-Andersen NJ, Oturai P, Munch-Andersen T, Borno A, et
al. (2011) Erythropoietin down-regulates proximal renal tubular reabsorption
and causes a fall in glomerular filtration rate in humans. J Physiol 589: 1273–
1281.
4. Lundby C, Olsen NV (2011) Effects of recombinant human erythropoietin in
normal humans. J Physiol 589: 1265–1271.
5. Franco RS (2009) The measurement and importance of red cell survival.
Am J Hematol 84: 109–114.
6. Rice L, Ruiz W, Driscoll T, Whitley CE, Tapia R, et al. (2001) Neocytolysis on
descent from altitude: a newly recognized mechanism for the control of red cell
mass. Ann Intern Med 134: 652–656.
7. Rice L, Alfrey CP (2005) The negative regulation of red cell mass by
neocytolysis: physiologic and pathophysiologic manifestations. Cell Physiol
Biochem 15: 245–250.
8. Chang CC, Chen Y, Modi K, Awar O, Alfrey C, et al. (2009) Changes of red
blood cell surface markers in a blood doping model of neocytolysis. J Investig
Med 57: 650–654.
9. Alfrey CP, Rice L, Udden MM, Driscoll TB (1997) Neocytolysis: physiological
down-regulator of red-cell mass. Lancet 349: 1389–1390.
10. Schmidt W, Prommer N (2005) The optimised CO-rebreathing method: a new
tool to determine total haemoglobin mass routinely. Eur J Appl Physiol 95: 486–
495.
11. Durussel J, Ross R, Raj Kodi P, Daskalaki E, Pantazis T, et al. (2011) Precision
of the optimized carbon monoxide rebreathing method to determine total
haemoglobin mass and blood volume. Eur J Sport Sci.
12. Noakes TD (2008) Testing for maximum oxygen consumption has produced a
brainless model of human exercise performance. Br J Sports Med 42: 551–555.
13. Shephard RJ (2009) Is the measurement of maximal oxygen intake passe?
Br J Sports Med 43: 83–85.
14. Costill DL, Thomason H, Roberts E (1973) Fractional utilization of the aerobic
capacity during distance running. Med Sci Sports 5: 248–252.
15. Levine BD, Stray-Gundersen J (1992) A practical approach to altitude training:
where to live and train for optimal performance enhancement. International
journal of sports medicine 13 Suppl 1: S209–212.
16. Thomsen JJ, Rentsch RL, Robach P, Calbet JA, Boushel R, et al. (2007)
Prolonged administration of recombinant human erythropoietin increases
submaximal performance more than maximal aerobic capacity. Eur J Appl
Physiol 101: 481–486.
17. Noakes TD (2008) Mechanism by which rHuEPO improves submaximal
exercise performance. Eur J Appl Physiol 103: 485.
18. Millet GP, Roels B, Schmitt L, Woorons X, Richalet JP (2010) Combining
hypoxic methods for peak performance. Sports medicine 40: 1–25.
19. Laursen PB, Francis GT, Abbiss CR, Newton MJ, Nosaka K (2007) Reliability
of time-to-exhaustion versus time-trial running tests in runners. Med Sci Sports
Exerc 39: 1374–1379.
20. Ahlgrim C, Pottgiesser T, Robinson N, Sottas PE, Ruecker G, et al. (2010) Are
10 min of seating enough to guarantee stable haemoglobin and haematocrit
readings for the athlete’s biological passport? Int J Lab Hematol 32: 1–6.
21. Kirkeberg JM, Dalleck LC, Kamphoff CS, Pettitt RW (2011) Validity of 3
protocols for verifying VO2 max. Int J Sports Med 32: 266–270.
22. Pettitt RW, Clark IE, Ebner SM, Sedgeman DT, Murray SR (2012) Gas
Exchange Threshold and VO2max Testing for Athletes: An Update. J Strength
Cond Res.
23. Russell G, Gore CJ, Ashenden MJ, Parisotto R, Hahn AG (2002) Effects of
prolonged low doses of recombinant human erythropoietin during submaximal
and maximal exercise. Eur J Appl Physiol 86: 442–449.
24. Audran M, Gareau R, Matecki S, Durand F, Chenard C, et al. (1999) Effects of
erythropoietin administration in training athletes and possible indirect detection
in doping control. Med Sci Sports Exerc 31: 639–645.
25. Birkeland KI, Stray-Gundersen J, Hemmersbach P, Hallen J, Haug E, et al.
(2000) Effect of rhEPO administration on serum levels of sTfR and cycling
performance. Med Sci Sports Exerc 32: 1238–1243.
26. Berglund B, Ekblom B (1991) Effect of recombinant human erythropoietin
treatment on blood pressure and some haematological parameters in healthy
men. J Intern Med 229: 125–130.
27. Wilkerson DP, Rittweger J, Berger NJ, Naish PF, Jones AM (2005) Influence of
recombinant human erythropoietin treatment on pulmonary O2 uptake kinetics
during exercise in humans. J Physiol 568: 639–652.
28. Parisotto R, Gore CJ, Emslie KR, Ashenden MJ, Brugnara C, et al. (2000) A
novel method utilising markers of altered erythropoiesis for the detection of
recombinant human erythropoietin abuse in athletes. Haematologica 85: 564–
572.
29. Connes P, Perrey S, Varray A, Prefaut C, Caillaud C (2003) Faster oxygen
uptake kinetics at the onset of submaximal cycling exercise following 4 weeks
recombinant human erythropoietin (r-HuEPO) treatment. Pflugers Arch 447:
231–238.
30. Mujika I, Padilla S (2001) Physiological and performance characteristics of male
professional road cyclists. Sports Med 31: 479–487.
31. Lucia A, Hoyos J, Perez M, Santalla A, Chicharro JL (2002) Inverse relationship
between VO2max and economy/efficiency in world-class cyclists. Med Sci
Sports Exerc 34: 2079–2084.
32. Brien AJ, Simon TL (1987) The effects of red blood cell infusion on 10-km race
time. JAMA 257: 2761–2765.
33. Boning D, Maassen N, Pries A (2008) No proof for augmented arterial oxygen
content as only factor influencing exercise capacity after Epo doping. J Appl
Physiol 105: 1988; author reply 1989.
34. Boning D, Maassen N, Pries A (2011) The hematocrit paradox–how does blood
doping really work? Int J Sports Med 32: 242–246.
35. Ninot G, Connes P, Caillaud C (2006) Effects of recombinant human
erythropoietin injections on physical self in endurance athletes. J Sports Sci
24: 383–391.
36. Miskowiak K, Inkster B, Selvaraj S, Wise R, Goodwin GM, et al. (2008)
Erythropoietin improves mood and modulates the cognitive and neural
processing of emotion 3 days post administration. Neuropsychopharmacology
33: 611–618.
37. Jelkmann W, Depping R, Metzen E (2009) Nonhematopoietic effects of
erythropoiesis-stimulating agents. In: Elliott SG, Foote M, Molineux G, editors.
Erythropoietin, Erythropoietic Factores, and Erythropoiesis. Basel: Birkha¨user.
299–317.
38. Brines M, Cerami A (2005) Emerging biological roles for erythropoietin in the
nervous system. Nat Rev Neurosci 6: 484–494.
Hbmass and Running Performance after rHuEpo
PLOS ONE | www.plosone.org 7 February 2013 | Volume 8 | Issue 2 | e56151
39. Ehrenreich H, Bartels C, Sargin D, Stawicki S, Krampe H (2008) Recombinant
human erythropoietin in the treatment of human brain disease: focus on
cognition. J Ren Nutr 18: 146–153.
40. Lundby C, Robach P, Boushel R, Thomsen JJ, Rasmussen P, et al. (2008) Does
recombinant human Epo increase exercise capacity by means other than
augmenting oxygen transport? J Appl Physiol 105: 581–587.
41. Rasmussen P, Foged EM, Krogh-Madsen R, Nielsen J, Nielsen TR, et al. (2010)
Effects of erythropoietin administration on cerebral metabolism and exercise
capacity in men. J Appl Physiol 109: 476–483.
42. Heinicke K, Wolfarth B, Winchenbach P, Biermann B, Schmid A, et al. (2001)
Blood volume and hemoglobin mass in elite athletes of different disciplines.
Int J Sports Med 22: 504–512.
43. Morkeberg J, Sharpe K, Belhage B, Damsgaard R, Schmidt W, et al. (2009)
Detecting autologous blood transfusions: a comparison of three passport
approaches and four blood markers. Scand J Med Sci Sports: 1–9.
44. Banfi G (2008) Reticulocytes in sports medicine. Sports Med 38: 187–211.
45. Belcher JD, Beckman JD, Balla G, Balla J, Vercellotti G (2010) Heme
degradation and vascular injury. Antioxid Redox Signal 12: 233–248.
46. Ryter SW, Otterbein LE (2004) Carbon monoxide in biology and medicine.
Bioessays 26: 270–280.
47. Engel RR, Rodkey FL, Krill CE, Jr. (1971) Carboxyhemoglobin levels as an
index of hemolysis. Pediatrics 47: 723–730.
Hbmass and Running Performance after rHuEpo
PLOS ONE | www.plosone.org 8 February 2013 | Volume 8 | Issue 2 | e56151
